Dernières nouvelles pour Elevation Oncology (NASDAQ:ELEV) Stock

Elevation Oncology

Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

Elevation Oncology Inc

Elevance Health Inc

ELEVATE URANIUM LTD by Elevate Uranium Ltd.

Elevate Uranium Ltd

Elevation Gold Mining Corp

ELEVATION GOLD MNG CORP by Elevation Gold Mining Corporation

Elevation Series Trust Clough Hedged Equity ETF

Elevation Series Trust Clough Select Equity ETF

Elevation Series Trust SRH REIT Covered Call ETF

Elevation Series Trust Sovereign's Capital Flourish Fund

Elevation Series Trust The Opal International Dividend Income ETF

Elevation Series Trust TrueShares Quarterly Bear Hedge ETF

Elevation Series Trust TrueShares Quarterly Bull Hedge ETF

Elevation Series Trust TrueShares Seasonality Laddered Buffered ETF

-- Abstract accepted for late-breaking poster presentation –
-- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers --
-- On-track to file an Investigational New Drug (IND) application in 2026 –

Biotech

News

Events

General

ELEV

Elevation Oncology To Present Data For EO-1022 At American Association for Cancer Research Annual Meeting 2025

Stephens &amp; Co. analyst Sudan Loganathan downgrades Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) from Overweight to Equal-Weight and lowers the price target from $5 to $1.

Downgrades

Price Target

Analyst Ratings

Stephens & Co. Downgrades Elevation Oncology to Equal-Weight, Lowers Price Target to $1

Piper Sandler analyst Biren Amin downgrades Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) from Overweight to Neutral and lowers the price target from $10 to $0.7.

Piper Sandler Downgrades Elevation Oncology to Neutral, Lowers Price Target to $0.7

Citizens Capital Markets analyst Silvan Tuerkcan downgrades Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) from Market Outperform to Market Perform and maintains the price target from $7 to $7.

Citizens Capital Markets Downgrades Elevation Oncology to Market Perform, Maintains Price Target to $7

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) price target from $341 to $370. Wells Fargo analyst Elyse Greenspan maintained an Overweight rating. Arthur J. Gallagher shares closed at $334.44 on Thursday.<a href="https://www.benzinga.com/quote/AJG/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Truist Securities cut the price target for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from $90 to $82. Truist Securities analyst Joseph Civello maintained a Buy rating. Nike shares closed at $71.86 on Thursday. See how other analysts <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">view this stock</a>.</li>
<li>BMO Capital slashed Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) price target from $58 to $54. BMO Capital analyst Katja Jancic maintained a Market Perform rating. Commercial Metals shares closed at $47.36 on Thursday. <a href="https://www.benzinga.com/quote/CMC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities cut the price target for Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) from $70 to $65. B. Riley Securities analyst Anna Glaessgen maintained a Buy rating. Academy Sports shares closed at $47.42 on Thursday. <a href="https://www.benzinga.com/quote/ASO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners lowered the price target for Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) from $9 to $1. Leerink Partners analyst Andrew Berens downgraded the stock from Outperform to Market Perform. Elevation Oncology shares closed at $0.2780 on Thursday. See how other analysts <a href="https://www.benzinga.com/quote/ELEV/analyst-ratings">view this stock</a>.</li>
<li>JP Morgan raised Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) price target from $35 to $45. JP Morgan analyst Samik Chatterjee upgraded the stock from Underweight to Neutral. Super Micro Computer shares settled at $39.10 on Thursday. <a href="https://www.benzinga.com/quote/SMCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) price target from $218 to $230. Oppenheimer analyst Brian Bittner maintained an Outperform rating. Darden shares closed at $199.01 on Thursday. <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) price target from $130 to $163. Baird analyst Tristan Gerra maintained an Outperform rating. Micron shares closed at $103.00 on Thursday. &nbsp;<a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased the price target for Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) from $5 to $6. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Torrid Holdings shares settled at $5.53 on Thursday. <a href="https://www.benzinga.com/quote/CURV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $430 to $410. Morgan Stanley analyst Adam Jonas maintained an Overweight rating. Tesla shares closed at $236.26 on Thursday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>
Photo: Shutterstock

Markets

CURV

SMCI

TSLA

Tesla To $410? Here Are 10 Top Analyst Forecasts For Friday

Leerink Partners analyst Andrew Berens downgrades Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) from Outperform to Market Perform and lowers the price target from $9 to $1.

Leerink Partners Downgrades Elevation Oncology to Market Perform, Lowers Price Target to $1

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) with a Buy and lowers the price target from $6 to $1.

HC Wainwright & Co. Maintains Buy on Elevation Oncology, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 226.4% to $1.73 during Thursday's regular session. The market value of their outstanding shares is at $19.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 205.28% to $1.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock moved upwards by 54.63% to $9.28. The company's market cap stands at $93.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 31.36% to $2.22. The company's market cap stands at $1.6 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock moved upwards by 27.84% to $11.98. The company's market cap stands at $98.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) stock moved upwards by 26.43% to $14.73. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 38.8% to $0.29 during Thursday's regular session. The company's market cap stands at $17.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 28.51% to $0.32. The market value of their outstanding shares is at $82.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares declined by 28.35% to $2.04. The company's market cap stands at $480.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 20.28% to $2.59. The company's market cap stands at $1.7 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 18.76% to $1.43. The market value of their outstanding shares is at $46.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 17.1% to $1.94. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

AKBA

BDRX

CRVO

OPTN

PSTV

RMTI

SPRY

VERO

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
The Dow traded up 0.63% to 42,230.78 while the NASDAQ climbed 0.81% to 17,894.89. The S&amp;P 500 also rose, gaining, 0.61% to 5,710.13.
Check This Out: <a href="https://www.benzinga.com/25/03/44414809/tesla-to-450-here-are-10-top-analyst-forecasts-for-thursday">Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday</a>
Leading and Lagging Sectors Communication services shares rose by 1.4% on Thursday.
In trading on Thursday, consumer staples shares fell by 0.1%.
Top Headline
U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) shares shot up 48% to $22.99 after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
<li>Shares of Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>)got a boost, surging 71% to $2.8950 after the company entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem&#8217;s PHEXXI.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares were also up, gaining 55% to $9.28 after Paratek Pharmaceuticals announced it will acquire the company in a deal worth $330 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares dropped 41% to $0.2798 after the company announced the discontinued development of EO-3021.</li>
<li>Shares of Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) were down 42% to $0.3755 after the company filed for Chapter 11 bankruptcy.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) was down, falling 30% to $1.9950 after the company announced the pricing of a $50 million offering of 25 million common shares at $2/share.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $68.00 while gold traded up 0.1% at $3,044.60.
Silver traded down 0.6% to $34.015 on Thursday, while copper fell 0.1% to $5.0930.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.47%, Germany's DAX 40 fell 1.43% and France's CAC 40 fell 0.86%. Spain's IBEX 35 Index fell 0.97%, while London's FTSE 100 slipped 0.15%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with China's Shanghai Composite Index falling 0.51%, Hong Kong's Hang Seng Index dipped 2.23% and India's BSE Sensex gaining 1.19%.
Economics
<ul>
<li>U.S. existing home sales increased by 4.2% from the previous month to an annualized rate of 4.26 million homes in February.</li>
<li>The U.S. current account deficit shrank by 2.0% to $303.9 billion in the fourth quarter, versus a revised deficit of $310.3 billion in the third quarter.</li>
<li>U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell to 12.5 in March from 18.1 in the previous month, versus market estimates of 8.5.</li>
<li>U.S. natural gas stocks increased 9 billion cubic feet in the week ending March 14, compared to market estimates of a 3 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415297/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q2 Earnings</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

BHIL

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase

On Thursday, Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
The company was developing a treatment for advanced, unresectable or metastatic gastric and <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">gastroesophageal junction cancers</a>.
The decision came due to disappointing data from the dose escalation and expansion stages of <a href="https://www.benzinga.com/pressreleases/25/03/n44414417/elevation-oncology-to-discontinue-development-of-eo-3021-advancing-eo-1022-while-evaluating-strate" target="_blank" rel="noreferrer noopener">Elevation Oncology&#8217;s Phase 1 trial</a>.
Treatment with EO-3021 as monotherapy demonstrated an objective response rate of 22.2% (1 confirmed complete response and 7 confirmed partial responses) and a disease control rate of 72.2% among 36 evaluable patients with gastric or GEJ cancer and Claudin 18.2 in ≥20% of tumor cells at IHC 2+/3+.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42793169/penny-stock-elevation-oncology-positioned-for-high-growth-in-antibody-drug-conjugates-market-analyst-sees-favorable-risk-to-reward-ratio" rel="noreferrer noopener">Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise</a>
In the safety analysis of all enrolled patients (n=85), treatment with EO-3021 was observed to be generally well-tolerated.
Treatment with EO-3021 did not meet the company&#8217;s &#8220;bar for success,&#8221; said Elevation Oncology CEO Joseph Ferra.
Elevation Oncology will continue to advance EO-1022, a HER3 ADC for patients with HER3-expressing solid tumors. The company plans to file an Investigational New Drug (IND) application in 2026.
In parallel, the company is initiating a process to evaluate strategic options to maximize shareholder value.
Elevation Oncology is implementing a workforce reduction of approximately 70%. The layoffs will result in total cash payments and costs of approximately $3 million.
As part of this reduction, Elevation Oncology&#8217;s Chief Medical Officer, Valerie Malyvanh Jansen, will step down, effective March 31.
Elevation Oncology expects that its cash, cash equivalents, and marketable securities of $93.2 million as of Dec. 31, will be sufficient to fund its operations into the second half of 2026.
Price Action: ELEV stock is down 47.1% at 25 cents at the last check Thursday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415537/shoe-carnival-q4-earnings-sales-miss-eps-beat-new-shoe-station-strategy-gloomy-outlook-and-more" target="_blank" rel="noreferrer noopener">Shoe Carnival Q4 Earnings: Sales Miss &amp; EPS Beat, New Shoe Station Strategy, Gloomy Outlook, And More</a></li>
</ul>

Health Care

Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.25% to 42,070.99 while the NASDAQ climbed 0.37% to 17,817.11. The S&amp;P 500 also rose, gaining, 0.28% to 5,689.83.
Check This Out: <a href="https://www.benzinga.com/25/03/44414809/tesla-to-450-here-are-10-top-analyst-forecasts-for-thursday">Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 0.7% on Thursday.
In trading on Thursday, materials shares fell by 0.3%.
Top Headline
Shares of Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) fell more than 7% on Thursday after the company reported results for the second quarter.
The company reported second-quarter 2025 earnings of $2.82 per share, slightly above the consensus of $2.81. The company reported sales of $16.66 billion, almost in line with the consensus of $16.62 billion and management guidance of $16.2 billion–$16.8 billion.
Accenture narrowed its fiscal year 2025 revenue growth outlook to 5%-7% in local currency, compared to prior guidance of 4%-7%. The company forecasts 2025 diluted earnings of $12.55-$12.79 per share compared to the consensus of $12.90.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SAG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares shot up 107% to $1.3995.</li>
<li>Shares of Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>)got a boost, surging 59% to $2.6900 after the company entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem&#8217;s PHEXXI.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares were also up, gaining 57% to $9.39 after Paratek Pharmaceuticals announced it will acquire the company in a deal worth $330 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares dropped 47% to $0.2501 after the company announced the discontinued development of EO-3021.</li>
<li>Shares of Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) were down 45% to $0.3570 after the company filed for Chapter 11 bankruptcy.</li>
<li>Adaptimmune Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) was down, falling 31% to $0.3088 after the company issued fourth-quarter and full year 2024 business update.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $67.50 while gold traded down 0.1% at $3,040.20.
Silver traded down 0.6% to $33.985 on Thursday, while copper fell 0.4% to $5.0815.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX 40 fell 1.2% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 0.9%, while London's FTSE 100 slipped 0.1%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with China's Shanghai Composite Index falling 0.51%, Hong Kong's Hang Seng Index dipped 2.23% and India's BSE Sensex gaining 1.19%.
Economics
<ul>
<li>U.S. existing home sales increased by 4.2% from the previous month to an annualized rate of 4.26 million homes in February.</li>
<li>The U.S. current account deficit shrank by 2.0% to $303.9 billion in the fourth quarter, versus a revised deficit of $310.3 billion in the third quarter.</li>
<li>U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell to 12.5 in March from 18.1 in the previous month, versus market estimates of 8.5.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415297/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q2 Earnings</a></li>
</ul>

Photo: Shutterstock

Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results

WIIM

Elevation Oncology shares are trading lower after the company announced the discontinued development of EO-3021.

-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation --&nbsp; -- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026 -- -- Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further development of EO-3021 -- -- Implementing workforce reduction of approximately 70%; cash runway extended into 2H 2026 --
BOSTON, March 20, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug conjugate (ADC), which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. Elevation Oncology will continue to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors, and, in parallel, is initiating a process to evaluate strategic options to maximize shareholder value.
The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of Elevation Oncology's Phase 1 trial, in which treatment with EO-3021 as a monotherapy demonstrated an objective response rate (ORR) of 22.2% (95% CI: 10, 39; 1 confirmed complete response and 7 confirmed partial responses) and a disease control rate (DCR) of 72.2% (95% CI: 55, 86) among 36 evaluable patients with gastric or GEJ cancer and Claudin 18.2 in ≥20% of tumor cells at IHC 2+/3+. In the safety analysis of all enrolled patients (n=85), treatment with EO-3021 was observed to be generally well-tolerated, with an adverse event profile consistent with previously reported data, including minimal hematological toxicity and hepatotoxicity, and no peripheral neuropathy/hypoesthesia.

Elevation Oncology To Discontinue Development Of EO-3021; Continuing To Advance Potentially Differentiated HER3 ADC, EO-1022, Which Utilizes An MMAE Payload And Glycan Site-Specific Conjugation

<h3>Gainers</h3>
<ul>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares moved upwards by 19.6% to $0.41 during Thursday's after-market session. The market value of their outstanding shares is at $1.1 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 14.83% to $0.69. The company's market cap stands at $16.3 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares moved upwards by 14.28% to $0.8. The market value of their outstanding shares is at $3.3 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares rose 9.69% to $0.43. The company's market cap stands at $26.5 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock moved upwards by 9.54% to $1.6. The market value of their outstanding shares is at $30.8 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares increased by 8.0% to $0.54. The company's market cap stands at $31.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock decreased by 17.5% to $0.27 during Thursday's after-market session. The company's market cap stands at $1.3 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares fell 11.76% to $0.23. The market value of their outstanding shares is at $6.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares fell 8.53% to $0.55. The market value of their outstanding shares is at $1.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 7.67% to $13.01. The company's market cap stands at $169.2 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 7.44% to $3.61. The company's market cap stands at $5.0 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock decreased by 7.17% to $0.14. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

BSGM

ENSC

NAYA

OSRH

PASG

PLRZ

TNFA

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's After-Market Session

Citizens Capital Markets analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) with a Market Outperform and maintains $7 price target.

Reiteration

Citizens Capital Markets Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) with a Buy and maintains $6 price target.

HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target

Stephens &amp; Co. analyst Sudan Loganathan reiterates Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) with a Overweight and maintains $5 price target.

Stephens & Co. Reiterates Overweight on Elevation Oncology, Maintains $5 Price Target

Earnings Beats

Elevation Oncology Q4 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate

Elevation Oncology shares are trading higher after the company announced it advanced its EO-3021 trial to target advanced gastric and GEJ cancers with improved care.

Press Releases

Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

Comments

Elevation Oncology

Actualités

Dernières nouvelles pour Elevation Oncology (NASDAQ:ELEV) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL